PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company.

Read Full Press Release

Scroll to top